A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility. The European Medicines Agency’s (EMA’s) ...
Stage at diagnosis remains the strongest determinant of cancer survival, yet only 13% of cancers are detected through guideline-based screening, and 20–50% first present in an emergency department.
NTRK (neurotrophic receptor tyrosine kinase)-rearranged spindle cell tumours are rare sarcomas predominantly occurring in the ...
Merck & Co.’s almighty Keytruda has become the first PD-1 inhibitor to show a benefit as a single agent for the front-line treatment of a subtype of endometrial cancer. Keytruda significantly improved ...
A new treatment for endometrial cancer demonstrated strong potential in a Phase 3 clinical trial. Drugmaker Merck announced Monday that the investigational drug sacituzumab tirumotecan (sac-TMT) met ...
A new treatment for endometrial cancer demonstrated strong potential in a Phase 3 clinical trial. Drugmaker Merck announced Monday that the investigational drug sacituzumab tirumotecan (sac-TMT) met ...
Over the last 18 months, Merck and Kelun-Biotech have notched four approvals in China for their TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT). And now, after meeting ...
May 18 (Reuters) - Merck (MRK.N), opens new tab said on Monday its experimental drug helped certain patients with uterine cancer live longer and kept their disease from worsening in ‌a late-stage ...
A breast cancer drug could provide new options for people suffering from treatment-resistant uterine cancer, according to new Yale School of Medicine (YSM) research. Uterine cancer is the deadliest ...
Overall, 91% of patients agreed that they would like to know about treatment options besides chemotherapy. Patients with endometrial cancer want an individualized, collaborative approach to their ...
Drs Ursula A. Matulonis and David G. Mutch discuss past and present endometrial cancer research, including the Route 66 SPORE. Drs Ursula Matulonis and Brian Slomovitz discuss phase 3 trials of ADCs ...
A panel of oncologists, pharmacists, and physician assistants discussed prevalent regimens for patients with recurrent endometrial cancer. Among the many conversations floating around the recurrent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results